Cargando…

Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant

PURPOSE: The aim of this study was to describe the clinical course and outcomes of four lung transplant recipients in the CD10 trial (NCT04343651): use of leronlimab (PRO 140), a novel humanized IgG4,κ monoclonal antibody to CCR5, for the treatment of mild-moderate COVID-19 illness. METHODS: Four el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skendelas, J.P., Phan, D., Caputo, V., Stryker, K., Ahmed, S., Philippsborn, P., Thalappillil, J., Scheinin, S.A., Seethamraju, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	(776)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979406/ http://dx.doi.org/10.1016/j.healun.2021.01.891

Ejemplares similares

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

The United States Experience of Lung Transplantation in Recipients with COVID-19 Fibrosis: A UNOS/OPTN Analysis
por: Phan, D.K., et al.
Publicado: (2022)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
por: Bekker, Pirow, et al.
Publicado: (2015)

Utility of CMR in identification of post lung transplant cardiovascular complications
por: Forouzandeh, Farshad, et al.
Publicado: (2012)

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model
por: Okamoto, Masayuki, et al.
Publicado: (2013)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

COVID-19 Vaccine Triggered Rejection in Lung Transplant Recipients: A Case Series
por: Alsunaid, S., et al.
Publicado: (2022)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Persistent hypoxemia and platypnea-orthodeoxia after left single-lung transplantation: a case report
por: Salim, Hamza, et al.
Publicado: (2015)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

In silco analysis of carboxamide derivatives of piperidine as potential antagonists of CCR5
por: Harishchander, A, et al.
Publicado: (2014)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Evolution of coreceptor utilization to escape CCR5 antagonist therapy
por: Zhang, Jie, et al.
Publicado: (2016)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
por: Sun, Zhe, et al.
Publicado: (2011)

Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study
por: Kothandan, Gugan, et al.
Publicado: (2012)

CCR3 antagonist impairs estradiol-induced eosinophil migration to the uterus in ovariectomized mice
por: Araújo, J.M.D., et al.
Publicado: (2019)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives as CCR5 Antagonists
por: Liu, Tao, et al.
Publicado: (2013)

Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis
por: Amerzhanova, Yerkezhan, et al.
Publicado: (2022)

A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma
por: Zhang, Yang, et al.
Publicado: (2017)

Δccr5 Genotype Is Associated with Mild Form of Nephropathia Epidemica
por: Kletenkov, Konstantin, et al.
Publicado: (2019)

Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for T(H)2-Specific Chemokine Receptors CCR3, CCR4, and CCR8
por: Matsuo, Kazuhiko, et al.
Publicado: (2016)

A Highly Selective Cc Chemokine Receptor (Ccr)8 Antagonist Encoded by the Poxvirus Molluscum Contagiosum
por: Lüttichau, Hans R., et al.
Publicado: (2000)

Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease
por: Lee, Jung-Kyu, et al.
Publicado: (2019)

Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis
por: Liu, Suxing, et al.
Publicado: (2021)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists
por: Ajram, Laura, et al.
Publicado: (2014)

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
por: Liu, Yanqing, et al.
Publicado: (2008)

Small Molecule CCR4 Antagonists Protect Mice from Aspergillus Infection and Allergy
por: Bozza, Silvia, et al.
Publicado: (2021)

Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021)

Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas’ Heart Disease: Antagonistic Participation of CCR1(+) and CCR5(+) Cells in Chronic Chagasic Cardiomyopathy
por: Batista, Angelica Martins, et al.
Publicado: (2018)

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
por: Arimura, Ken, et al.
Publicado: (2023)

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmd(mdx-4Cv)) mice
por: Liang, Feng, et al.
Publicado: (2018)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Systematic Assessment of Chemokine Signaling at Chemokine Receptors CCR4, CCR7 and CCR10
por: Lim, Herman D., et al.
Publicado: (2021)

Publisher Correction: A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma
por: Zhang, Yang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9gdjnuk17bajdk8u14fnakm9bm